RT Journal Article SR Electronic T1 Interplay between Chronic Kidney disease, Hypertension, and Stroke: Insights from a Multivariable Mendelian Randomization Analysis JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2022.09.14.22279923 DO 10.1101/2022.09.14.22279923 A1 Dearbhla M. Kelly A1 Marios K. Georgakis A1 Nora Franceschini A1 Deborah Blacker A1 Anand Viswanathan A1 Christopher D. Anderson YR 2022 UL http://medrxiv.org/content/early/2022/09/17/2022.09.14.22279923.abstract AB Background and Objectives Chronic kidney disease (CKD) increases the risk of stroke, but the extent through which this association is mediated by hypertension is unknown. We leveraged large-scale genetic data to explore causal relationships between CKD, hypertension and cerebrovascular disease phenotypes.Methods We used data from genome-wide association studies (GWAS) of European ancestry to identify genetic proxies for kidney function (CKD diagnosis, estimated glomerular filtration rate [eGFR], and urinary albumin-to-creatinine ratio [UACR]), systolic blood pressure (SBP), and cerebrovascular disease (ischaemic stroke and its subtypes, and intracerebral haemorrhage [ICH). We then conducted univariable, multivariable and mediation Mendelian randomization (MR) analyses to investigate the effect of kidney function on stroke risk and the proportion of this effect mediated through hypertension.Results Univariable Mendelian randomization revealed associations between genetically determined lower eGFR and risk of all stroke (OR per 1-log decrement in eGFR, 1.77; 95% CI, 1.31-2.40; p<0.001), ischaemic stroke (OR, 1.81; 95% CI, 1.31-2.51; p<0.001), and most strongly with large artery stroke (LAS) (OR, 3.00; 95% CI, 1.33-6.75; p=0.008). These associations remained significant in the multivariable MR analysis, controlling for SBP (OR, 1.98; 95% CI, 1.39-2.82; p<0.001 for AS; OR, 2.16; 95% CI, 1.48-3.17; p<0.001 for IS; OR, 4.35; 95% CI, 1.84-10.27; p=0.001 for LAS). with only a small proportion of the total effects mediated by SBP (10.5%, 6.6% and 7.8%, respectively). Total, direct and indirect effect estimates were similar across a number of sensitivity analyses.Discussion Our results demonstrate an independent causal effect of impaired kidney function, as assessed by decreased eGFR, on stroke risk, particularly LAS, even when controlled for SBP. Targeted prevention of kidney disease could lower atherosclerotic stroke risk independent of hypertension.Competing Interest StatementThe authors have declared no competing interest.Funding StatementDMK is an Atlantic Fellow for Equity in Brain Health at the Global Brain Health Institute (GBHI) and is supported with funding from GBHI, Alzheimers Association, and Alzheimers Society (GBHI ALZ UK22868940), and is the recipient of an NIH StrokeNet Fellowship. MKG is supported by a Walter Benjamin fellowship from the German Research Foundation (Deutsche Forschungsgemeinschaft [DFG], GZ: GE 3461/1 1) and the FoFoLe program of Ludwig Maximilians University Munich (FoFoLe Forschungsprojekt Reg. Nr. 1120). This work was funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy within the framework of the Munich Cluster for Systems Neurology (EXC 2145 SyNergy ID 390857198 to MKG). NF is supported by NIH RO1 HL163972. AV is supported by NIH P50 AG005134 NIH AG047975 R01 NS104130. CDA is supported by NIH R01NS103924, U01NS069673, AHA 18SFRN34250007, and AHA-Bugher 21SFRN812095 for this work. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesGenetic variants used are available in the supplemental information (eSupplement) and the code used for all analyses is available on request.